Purine Starvation Driven by Host-microbiota Maladaptation Contributes to the Pathogenesis of Irritable Bowel Syndrome

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. A senior gastroenterologist is responsible for prescribing medication. Researchers are blind to patients' medication. Participants with IBS are recruited and randomized to receive a 4-week administration of B. subtilis-based probiotics. Clinical symptoms and stool samples are collected before and after the trial.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Maximum Age: 80
Healthy Volunteers: t
View:

• Patients are diagnosed with IBS. IBS was diagnosed based on the Rome IV criteria. Subjects aged from 16-80 years old without any gut medical conditions like inflammatory bowel diseases, infectious diarrhea, colon tumors were included.

Locations
Other Locations
China
Jinling Hospital
RECRUITING
Nanjing
Jinling Hospital
RECRUITING
Nanjing
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 180
Treatments
Active_comparator: B. subtilis intervention
Placebo_comparator: Placebo capsules
Sponsors
Leads: Jinling Hospital, China

This content was sourced from clinicaltrials.gov

Similar Clinical Trials